Eligibility Pre-hypertension NCT01568983

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
pre-hypertension or hypertension systolic blood pressure in the 130-179 mmhg range and/or diastolic blood pressure in the 85-109 mmhg range)
Description

ID.1

Data type

boolean

bmi 20-35 kg/m2
Description

ID.2

Data type

boolean

stable weight (change <4 kg previous 12 weeks)
Description

ID.3

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
regular use of blood pressure lowering agens
Description

ID.4

Data type

boolean

diabetes type i or ii
Description

ID.5

Data type

boolean

smokers
Description

ID.6

Data type

boolean

allergy to grape, cherries, blueberries/bilberries, black currant, aronia
Description

ID.7

Data type

boolean

supplements for weight loss
Description

ID.8

Data type

boolean

changes in pharmacological treatment of hyperlipidemia or hyperglycemia (initiation, termination or changes in dosage) last 30 days prior to inclusion or during the study period (run-in and intervention)
Description

ID.9

Data type

boolean

participation in a drug trial during the previous 30 days
Description

ID.10

Data type

boolean

Similar models

Eligibility Pre-hypertension NCT01568983

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
pre-hypertension or hypertension systolic blood pressure in the 130-179 mmhg range and/or diastolic blood pressure in the 85-109 mmhg range)
boolean
ID.2
Item
bmi 20-35 kg/m2
boolean
ID.3
Item
stable weight (change <4 kg previous 12 weeks)
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
regular use of blood pressure lowering agens
boolean
ID.5
Item
diabetes type i or ii
boolean
ID.6
Item
smokers
boolean
ID.7
Item
allergy to grape, cherries, blueberries/bilberries, black currant, aronia
boolean
ID.8
Item
supplements for weight loss
boolean
ID.9
Item
changes in pharmacological treatment of hyperlipidemia or hyperglycemia (initiation, termination or changes in dosage) last 30 days prior to inclusion or during the study period (run-in and intervention)
boolean
ID.10
Item
participation in a drug trial during the previous 30 days
boolean